162046-38-0

Upstream product

• 610-36-6 4-amino-2-nitrobenzoic acid 

Downstream Products

• 301220-82-6 C₁₇H₂₀N₂ 
• 782493-45-2 tert-butyl 4-[4-fluoro-3-(methoxycarbonyl)phenyl]-3,6-dihydropyridine-1(2H)-carboxylate 
• 252330-19-1 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one 
• 1555377-05-3 tert-butyl 4-benzoyl-3,6-dihydro-2H-pyridine-1-carboxylate 
• 138647-53-7 1-tert-butyloxycarbonyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine 
• 301220-83-7 4-((5-benzyl)pyrid-3-yl)piperidine, trifluoroacetate salt 
• 607744-56-9 tert-butyl 4-(4-chloro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 607744-53-6 tert-butyl 4-{4-[acetyl(benzyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate 
• 906463-12-5 4-[5-(2-chloro-phenyl)-1-(2,6-dichloro-phenyl)-2-oxo-1,2,3,4-tetrahydro-pyrido[4,3-d]pyrimidin-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 444663-63-2 7-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-2(1H)-quinolinone 
• 444664-31-7 4-[1-(2,6-dichloro-phenyl)-5-(2,4-difluoro-phenyl)-2-oxo-1,2,3,4-tetrahydro-quinazolin-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 444665-23-0 tert-butyl 4-[5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-2-oxo-1,2-dihydroquinolin-7-yl]-3,6-dihydropyridine-1(2 H)-carboxylate 

Relevant academic research and scientific papers

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.